Rare Blood Diseases YIR

CME

Key Advances in Rare Blood Diseases in 2024: A Year in Review

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: January 30, 2025

Expiration: January 29, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following therapies is approved for routine prophylaxis in adult and pediatric patients 12 years of age or older with hemophilia A or B with factor VIII or factor IX inhibitors, respectively?